EULAT Eradicate GBC

Gallstones are relatively frequent in women and constitute one of the main risk factors for gallbladder cancer (GBC). Currently, GBC diagnosis is mainly based on imaging (ultrasound or abdominal CT) associated with invasive examinations (biopsy and surgery), with no marker available to date to accurately predict risk and diagnose the disease early. The only curative treatment for GBC remains surgery with complete resection of tumors in early stages. Given the aggressiveness of GBC and the very limited therapeutic options, as well as the possibility of preventing GBC by cholecystectomy during the 10 to 20 years required for the development of gallbladder tumors, it is imperative to develop effective and efficient prevention strategies based on a prioritization of interventions according to environmental and genetic-molecular risk factors. The investigators aim to identify epidemiological factors linked to the development of GBC, and to identify, validate and functionally characterize genetic-molecular markers in blood, saliva, urine, bile and stool that allow risk prediction, early diagnosis and precision treatment of incidental tumors.

NCT Number	NCT06192719
Lead Sponsor	Centre Paul Strauss Collaborators: University Hospital Heidelberg, Universidad Austral de Chile, Universidad de La Frontera, Universidad Católica del Maule, Centre international de recherche sur le cancer (IARC, France), University of Chile, Instituto Nacional de Enfermedades Neoplásicas (INEN, Peru), Universidad Mayor de San Simón (UMSS, Bolivia), Oslo University Hospital, Sanatorio el Carmen (Argentina), Pontificia Universidad Catolica de Chile, University of Bristol, University of Oslo, Chilean institutions (See detailed study description below), Peruvian institutions (See detailed study description below), Bolivian institutions (See detailed study description below), Argentinian institutions (See detailed study description below)
Conditions	Gallbladder Cancer, Gallstone Disease
Enrollment	15,000 participants
Start Date	2019-12-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-18